← Eichor
Study identifier: NCT00345930 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

DILIN - Prospective Study

Condition: Liver Diseases  ·  Sponsor: Duke University

PhaseN/A
Planned participants4000
Who can joinAll sexes, 2 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol. Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects.

This description comes directly from the study's public registry record.

Talk to the study team

Eilene Pham  ·  9196607253  ·  eilene.pham@duke.edu

Matt Baum  ·  919-668-0486  ·  matt.baum@duke.edu

Always discuss trial participation with your own doctor first.

Locations (6)

University of Southern CaliforniaLos Angeles, California, United StatesRecruiting
Indiana UniversityIndianapolis, Indiana, United StatesRecruiting
NIH Clinical SiteBethesda, Maryland, United StatesRecruiting
University of MichiganAnn Arbor, Michigan, United StatesRecruiting
Univeristy of North Carolina at Chapel HillChapel Hill, North Carolina, United StatesRecruiting
Thomas JeffersonPhiladelphia, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT00345930